Epic Sciences to Present Data at SABCS 2018
Epic Sciences, Inc. (Epic) announced today that they will be presenting new data on inter- and intra-patient phenotypic heterogeneity and the use of HER2 and AR expression in metastatic breast cancer circulating tumor cells at the 2018 San Antonio Breast Cancer Symposium (SABCS) from December 4 – 8 in San Antonio, TX. Epic will be showcasing this data during the Detection/Diagnosis: Circulating Tumor Cells session on December 6.
“Profiling single tumor cells for functional protein, morpohologic and genomic differences provides novel insights into understanding of tumor heterogeneity as it relates to clinical progression,” said Ryan Dittamore, chief of medical innovation at Epic Sciences. “We expect that our use of single cell pheno-genomics will enable insight into therapeutic resistance and may identify novel therapeutic opportunities in metastatic breast cancer.”
Following are the details for the two poster sessions:
Abstract: P3-01-07
Poster: Enabling HER2 and androgen receptor (AR) protein expression and localization in circulating tumor cells (CTCs) of ER(+/-)HER2(-) metastatic breast cancer (MBC) patients (pts),
Authors: Ontiveros P, Landaverde C, Graf R, Levin MK, Hippely S, Wang Y, Landers M, Dittamore R, O’Shaughnessy JA. Epic Sciences, San Diego, CA; Baylor Scott & White Research Institute, Dallas, TX.
Location: Hall 1
Date and Time: Thursday, December 6, 5:00 pm – 7:00 pm CST
Abstract: P3-01-14
Poster: Diverse inter- and intra-patient circulating tumor cells (CTCs) phenotypic heterogeneity identified in metastatic breast cancer (MBC) cohort.
Authors: Wang Y, Hom B, Ontiveros P, Landaverde C, Roth E, Levin MK, Hippely S, Landers M, Dittamore R, O’Shaughnessy JA. Epic Sciences, San Diego, CA; Baylor Scott & White Research Institute, Dallas, TX.
Location: Hall 1
Date and Time: Thursday, December 6, 5:00 pm – 7:00 pm CST
Visit Epic Sciences at Booth 222 for more information about Epic during SABCS.
About Epic Sciences
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences’ mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells. Epic Sciences No Cell Left Behind® technology helps match patients to therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DX® AR-V7 Nucleus DetectTM test, which helps with therapeutic decisions between taxane chemotherapy or androgen-directed therapeutics in metastatic castrate-resistant prostate cancer. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences’ goal is to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices. Epic Sciences is headquartered in San Diego.
Further information is available on the Company’s website, www.epicsciences.com. Stay in touch on LinkedIn or on Twitter @EpicSciences.
Epic Sciences Media Contact: Jennifer Guzman, Director of Marketing, jennifer.guzman@epicsciences.com, +1.858.216.2217